PIK3CA and head and neck squamous cell carcinoma: Alpelisib is an oral selective PI3Kα inhibitor, showing significantly improved objective response rates in patients with solid tumors harboring PIK3CA mutations (14.2% of HNSCC patients) than those with wild-type tumors.